<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621153</url>
  </required_header>
  <id_info>
    <org_study_id>D2452L00016</org_study_id>
    <nct_id>NCT00621153</nct_id>
  </id_info>
  <brief_title>Candesartan Effect in Second Stage Arterial Hypertension</brief_title>
  <acronym>CAESAR</acronym>
  <official_title>Open-label, Randomised, 2-Arm Parallel Group, Multicentre, 8-week, Phase IV Study to Assess the Antihypertensive Efficacy and Safety of the Candesartan Cilexetil 16 mg and Hydrochlorothiazide 12.5 mg Combination Therapy in Comparison With Candesartan 16 mg Monotherapy in Hypertensive Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the changes in mean sitting DBP from baseline after 4 weeks of therapy with either
      candesartan cilexetil/HCT combination therapy or candesartan cilexetil monotherapy regimen
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean of the changed DBP from baseline after 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Mean Sitting SBP From Baseline After 4 Weeks of Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Mean of the changed SBP from baseline after 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (&lt;90 mmHg, But &lt;80 mmHg for DM &amp; Chronic Kidney Disease) and SBP (&lt;140 mmHg, But &lt;130 mmHg for DM &amp; Chronic Kidney Disease) After 4 Weeks of Therapy</measure>
    <time_frame>4 weeks</time_frame>
    <description>Percent of the patients achieving goal DBP and SBP after 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (&lt;90 mmHg, But &lt;80 mmHg for DM &amp; Chronic Kidney Disease) and SBP (&lt;140 mmHg, But &lt;130 mmHg for DM &amp; Chronic Kidney Disease) After 8 Weeks of Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent of patients achieving goal of DBP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Mean Sitting SBP From Baseline After 8 Weeks of Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Changed SBP from baseline after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Hs-CRP Level From Baseline After 8 Weeks of Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Change of hs-CRP from basline after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Adverse Events (AE) and Discontinuation of Study Medication Due to AE's From Baseline (Randomisation) to the End of the Study (8 Weeks)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Occurred number of AE and disconinuation of study medication due to the AE from basline after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance Levels at 4 Weeks and 8 Weeks of Therapy</measure>
    <time_frame>8 weeks</time_frame>
    <description>Percent of the number of returened pills to the number of prescrited pills</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">214</enrollment>
  <condition>Stage II Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan cilexetil 16mg monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan cilexetil 16mg/HCT combination therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>candesartan cilexetil 32mg monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Candesartan Cilexetil 32 mg/HCT combination therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>Candesartan Cilexetil 16 mg oral</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 12.5 mg</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>HCTZ</other_name>
    <other_name>Diazide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan Cilexetil</intervention_name>
    <description>Candesartan Cilexetil 32 mg oral</description>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <other_name>Atacand</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stage II essential hypertension (SBP≥ 160 or DBP≥100 mmHg), untreated, or treated with
             a maximum of 2 class of antihypertensive drugs

        Exclusion Criteria:

          -  Current serum-creatinine &gt;3 mg/dL, Current serum-potassium &gt;5.5 mmol/L, 16.

          -  Pregnant or lactating women or women of childbearing potential who were not protected
             from pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dong Hoon Choi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joonwoo Bahn</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca Korea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2008</study_first_submitted>
  <study_first_submitted_qc>February 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <results_first_submitted>February 24, 2010</results_first_submitted>
  <results_first_submitted_qc>February 24, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 23, 2010</results_first_posted>
  <last_update_submitted>February 24, 2010</last_update_submitted>
  <last_update_submitted_qc>February 24, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 23, 2010</last_update_posted>
  <keyword>Candesartan Cilexetil</keyword>
  <keyword>hydrochlorothiazide</keyword>
  <keyword>severe hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>253 enrolled, 20 screening failure, 223 randomised, 198 completed</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Candesartan Cilexetil/Hydroclorozide Combination Therapy</title>
          <description>candesartan cilexetil/Hydroclorozide combination therapy</description>
        </group>
        <group group_id="P2">
          <title>Candesartan Cilexetil Monotherapy</title>
          <description>candesartan cilexetil monotherapy</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="117">randomised</participants>
                <participants group_id="P2" count="116">randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="97">completed</participants>
                <participants group_id="P2" count="101">completed</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Safety Reason</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Candesartan Cilexetil/Hydroclorozide Combination Therapy</title>
          <description>candesartan cilexetil/Hydroclorozide combination therapy</description>
        </group>
        <group group_id="B2">
          <title>Candesartan Cilexetil Monotherapy</title>
          <description>candesartan cilexetil monotherapy</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="117"/>
            <count group_id="B2" value="116"/>
            <count group_id="B3" value="233"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51.00" spread="10"/>
                    <measurement group_id="B2" value="47.80" spread="10"/>
                    <measurement group_id="B3" value="48.90" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75"/>
                    <measurement group_id="B2" value="78"/>
                    <measurement group_id="B3" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy</title>
        <description>Mean of the changed DBP from baseline after 4 weeks</description>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Candesartan Cilexetil/Hydroclorozide Combination Therapy</title>
            <description>candesartan cilexetil/Hydroclorozide combination therapy</description>
          </group>
          <group group_id="O2">
            <title>Candesartan Cilexetil Monotherapy</title>
            <description>candesartan cilexetil monotherapy</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Mean Sitting DBP From Baseline After 4 Weeks of Therapy</title>
          <description>Mean of the changed DBP from baseline after 4 weeks</description>
          <units>mmHg</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="111"/>
                <count group_id="O2" value="113"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.0" spread="0.89"/>
                    <measurement group_id="O2" value="-14.1" spread="0.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Mean Sitting SBP From Baseline After 4 Weeks of Therapy</title>
        <description>Mean of the changed SBP from baseline after 4 weeks</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (&lt;90 mmHg, But &lt;80 mmHg for DM &amp; Chronic Kidney Disease) and SBP (&lt;140 mmHg, But &lt;130 mmHg for DM &amp; Chronic Kidney Disease) After 4 Weeks of Therapy</title>
        <description>Percent of the patients achieving goal DBP and SBP after 4 weeks</description>
        <time_frame>4 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Achieving Goal of Mean Trough Sitting DBP (&lt;90 mmHg, But &lt;80 mmHg for DM &amp; Chronic Kidney Disease) and SBP (&lt;140 mmHg, But &lt;130 mmHg for DM &amp; Chronic Kidney Disease) After 8 Weeks of Therapy</title>
        <description>Percent of patients achieving goal of DBP</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Mean Sitting SBP From Baseline After 8 Weeks of Therapy</title>
        <description>Changed SBP from baseline after 8 weeks</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Hs-CRP Level From Baseline After 8 Weeks of Therapy</title>
        <description>Change of hs-CRP from basline after 8 weeks</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Adverse Events (AE) and Discontinuation of Study Medication Due to AE’s From Baseline (Randomisation) to the End of the Study (8 Weeks)</title>
        <description>Occurred number of AE and disconinuation of study medication due to the AE from basline after 8 weeks</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Compliance Levels at 4 Weeks and 8 Weeks of Therapy</title>
        <description>Percent of the number of returened pills to the number of prescrited pills</description>
        <time_frame>8 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Candesartan Cilexetil/Hydroclorozide Combination Therapy</title>
          <description>candesartan cilexetil/Hydroclorozide combination therapy</description>
        </group>
        <group group_id="E2">
          <title>Candesartan Cilexetil Monotherapy</title>
          <description>candesartan cilexetil monotherapy</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1"/>
                <counts group_id="E2" subjects_affected="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Breast clacifications</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Scrub typhus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6"/>
                <counts group_id="E2" subjects_affected="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="111"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="113"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <phone>+44 1509 64589 ext 4589</phone>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

